Cue Biopharma Raises $10.0M Series A

Cue Biopharma, a clinical-stage biopharmaceutical company, has successfully raised $10.0 million in new investment capital from investors.

This funding round provides significant financial support for the company's ongoing efforts in developing novel therapeutic biologics.

The capital infusion marks a key milestone as Cue Biopharma continues to advance its proprietary platform and clinical programs.

The company is focused on creating a new class of therapeutic biologics designed to selectively engage and modulate disease-relevant T cells.

These therapies are intended for the treatment of both autoimmune diseases and various forms of cancer.

Cue Biopharma's core technology is its Immuno-STAT® (Selective Targeting and Alteration of T Cells) platform.

This proprietary system and its associated biologics are engineered to harness the curative potential of the body’s innate immune system.

A primary goal of this approach is to achieve selective modulation of disease-relevant T cells, thereby avoiding the adverse effects often associated with broad systemic immune activation.

The $10.

0 million in secured funding is earmarked to accelerate Cue Biopharma's strategic growth initiatives.

Specifically, the capital will be directed towards advancing its existing clinical pipeline, supporting ongoing research and development efforts, and expanding the company's operational capabilities.

This investment is anticipated to enable Cue Biopharma to further explore the potential of its Immuno-STAT® platform and progress its therapeutic candidates through critical development stages.

This financial backing underscores the continued confidence in Cue Biopharma's innovative approach to immunotherapy.

The company remains committed to its mission of developing targeted treatments that leverage the body's own immune system to address complex diseases.

Cue Biopharma looks forward to leveraging this capital to drive its scientific advancements and ultimately bring its novel therapies closer to patients in need.